克隆性MET扩增作为表皮生长因子受体突变非小细胞肺癌酪氨酸激酶抑制剂耐药的决定因素
在200例初治转移性EGFR突变阳性NSCLC患者中,26%为MET高拷贝数(≥5),其中46例为多体、6例为扩增。MET高与低组的中位TTF无显著差异(12.2个月 vs 13.1个月,P=0.566),仅在MET扩增患者中观察到EGFR TKI应答欠佳。
要点
- 初治转移性EGFR突变NSCLC中26%为MET高拷贝数(≥5),仅3%为MET扩增。
- MET高与低组的中位TTF无显著差异(12.2个月 vs 13.1个月,P=0.566)。
- 合并MET扩增的5例(3.2%)患者对EGFR TKI应答欠佳(TTF 1.0-6.4个月)。
核心结论
- 尽管高达26%的初治EGFR突变阳性NSCLC经FISH检测存在高MET拷贝数,但除MET扩增患者外,这并未显著影响对TKI的应答。
- 数据强调了采用任意拷贝数阈值的局限性,以及需要跨检测方法验证以定义EGFR突变阳性NSCLC中可治疗性MET通路失调。
研究设计与样本
- 对200例连续确定的转移性初治EGFR突变阳性患者进行MET荧光原位杂交检测。
- MET高定义为拷贝数≥5,扩增额外要求MET/7号染色体着丝粒比值≥2。
- 对13例早期切除的EGFR突变阳性NSCLC的59个区域进行多区域单核苷酸多态性芯片分析以研究MET拷贝数增益的瘤内异质性。
主要发现
- 200例转移性队列中52例(26%)在诊断时为MET高,其中46例(23%)为多体、6例(3%)为扩增。
- MET高组与低组的中位TTF分别为12.2个月(95%CI 5.7-22.6个月)与13.1个月(95%CI 10.6-15.0个月),P=0.566。
- 无论拷贝数阈值如何,应答率无显著差异。
- 6例MET高患者中3例进展后活检显示MET丢失,与早期肿瘤中观察到的MET拷贝数增益显著瘤内异质性一致。
- 154例中5例(3.2%)合并MET扩增的患者对EGFR TKI应答欠佳(TTF 1.0-6.4个月)。
局限性
- 原文指出采用任意拷贝数阈值存在局限性。
- 原文指出需要跨检测方法验证以定义可治疗性MET通路失调。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Mesenchymal epithelial transition factor ( MET) activation has been implicated as an oncogenic driver in epidermal growth factor receptor ( EGFR)-mutant non-small-cell lung cancer (NSCLC) and can mediate primary and secondary resistance to EGFR tyrosine kinase inhibitors (TKI). High copy number thresholds have been suggested to enrich for response to MET inhibitors. We examined the clinical relevance of MET copy number gain (CNG) in the setting of treatment-naive metastatic EGFR-mutant-positive NSCLC. PATIENTS AND METHODS: MET fluorescence in situ hybridization was performed in 200 consecutive patients identified as metastatic treatment-naïve EGFR-mutant-positive. We defined MET-high as CNG greater than or equal to 5, with an additional criterion of MET/centromeric portion of chromosome 7 ratiο greater than or equal to 2 for amplification. Time-to-treatment failure (TTF) to EGFR TKI in patients identified as MET-high and -low was estimated by Kaplan-Meier method and compared using log-rank test. Multiregion single-nucleotide polymorphism array analysis was performed on 13 early-stage resected EGFR-mutant-positive NSCLC across 59 sectors to investigate intratumoral heterogeneity of MET CNG. RESULTS: Fifty-two (26%) of 200 patients in the metastatic cohort were MET-high at diagnosis; 46 (23%) had polysomy and six (3%) had amplification. Median TTF was 12.2 months (95% CI, 5.7 to 22.6 months) versus 13.1 months (95% CI, 10.6 to 15.0 months) for MET-high and -low, respectively ( P = .566), with no significant difference in response rate regardless of copy number thresholds. Loss of MET was observed in three of six patients identified as MET-high who underwent postprogression biopsies, which is consistent with marked intratumoral heterogeneity in MET CNG observed in early-stage tumors. Suboptimal response (TTF, 1.0 to 6.4 months) to EGFR TKI was observed in patients with coexisting MET amplification (five [3.2%] of 154). CONCLUSION: Although up to 26% of TKI-naïve EGFR-mutant-positive NSCLC harbor high MET CNG by fluorescence in situ hybridization, this did not significantly affect response to TKI, except in patients identified as MET-amplified. Our data underscore the limitations of adopting arbitrary copy number thresholds and the need for cross-assay validation to define therapeutically tractable MET pathway dysregulation in EGFR-mutant-positive NSCLC.
引用
- Lai GGY, Lim TH, Lim J, et al. Clonal MET Amplification as a Determinant of Tyrosine Kinase Inhibitor Resistance in Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer. J Clin Oncol. 2019. PMID: 30676858. doi:10.1200/JCO.18.00177
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。